Adamas Pharma (ADMS) Reports 1st Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment
Tweet Send to a Friend
Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) today announced that the first patient has been enrolled in its pivotal Phase 3 clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
